Platelet Inhibition by Aspirin 81 and 325 mg/day in Men Versus Women Without Clinically Apparent Cardiovascular Disease

American Journal of Cardiology

Volumn 101, Issue 9, 2008, Pages 1359-1363

  Qayyum, Rehan ^a   Becker, Diane M ^a   Yanek, Lisa R ^a   Moy, Taryn F ^a   Becker, Lewis C ^a   Faraday, Nauder ^a   Vaidya, Dhananjay ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; COLLAGEN; CYCLOOXYGENASE 1;

ADULT; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA;

ADULT; ASPIRIN; CARDIOVASCULAR DISEASES; FEMALE; HEMATOCRIT; HUMANS; LIPIDS; LOGISTIC MODELS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET FUNCTION TESTS; SEX FACTORS; STATISTICS, NONPARAMETRIC;

EID: 43049107140     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.12.038     Document Type: Article

References (14)

1. Becker D.M., Segal J., Vaidya D., Yanek L.R., Herrera-Galeano J.E., Bray P.F., Moy T.F., Becker L.C., and Faraday N. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 295 (2006) 1420-1427
2. Berger J.S., Roncaglioni M.C., Avanzini F., Pangrazzi I., Tognoni G., and Brown D.L. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295 (2006) 306-313
3. Dalen J.E. Aspirin to prevent heart attack and stroke: what's the right dose?. Am J Med 119 (2006) 198-202
4. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Jones D.W., Materson B.J., Oparil S., Wright Jr. J.T., and Roccella E.J. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
5. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
6. Kim M.T., Hill M.N., Bone L.R., and Levine D.M. Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs 15 (2000) 90-96
7. de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 357 (2001) 89-95
8. Hansson L., Zanchetti A., Carruthers S.G., Dahlof B., Elmfeldt D., Julius S., Menard J., Rahn K.H., Wedel H., and Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351 (1998) 1755-1762
9. Ridker P.M., Cook N.R., Lee I.M., Gordon D., Gaziano J.M., Manson J.E., Hennekens C.H., and Buring J.E. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005) 1293-1304
10. Gurbel P.A., Bliden K.P., Dichiara J., Newcomer J., Weng W., Neerchal N.K., Gesheff T., Chaganti S.K., Etherington A., and Tantry U.S. Evaluation of dose-related effects of aspirin on platelet function. Results from the Aspirin-Induced Platelet Effect (ASPECT) Study. Circulation 115 (2007) 3156-3164
11. Schafer A.I. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 35 (1995) 209-219
12. Campbell D.T., and Stanley J.C. Experimental and Quasi-experimental Designs for Research (1963), Houghton Mifflin Company, Boston 5-6
13. Ohmori T., Yatomi Y., Nonaka T., Kobayashi Y., Madoiwa S., Mimuro J., Ozaki Y., and Sakata Y. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 4 (2006) 1271-1278
14. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., and Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655